English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90429/105609 (86%)
Visitors : 10289748      Online Users : 292
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/17382

    Title: A Novel Orally Active Sulfonamide Compound Dipeptidyl Peptidase IV Inhibitor: Structure and Activity Relationship of Arylsulfonamide to Dipeptidyl Peptidase IV Inhibition
    Authors: 蔡建鈞;Tsai, Henry J;Chou, Shan-Yen;Chuang, SH;Chen, CC;Hsu, FL
    Contributors: 保健營養生技學系
    Keywords: dipeptidyl peptidase IV;inhibitor;sulfonamide;diabetes
    dipeptidyl peptidase IV;inhibitor;sulfonamide;diabetes
    Date: 2008-12
    Issue Date: 2012-11-26 10:32:16 (UTC+8)
    Abstract: Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are two incretin peptide hormones secreted from the intestine to synergize insulin's function at lowering blood glucose. The effects of GLP-1 or GIP administration are short-lived because they are rapidly inactivated by circulating dipeptidyl peptidase IV (DPP-IV). Therefore, DPP-IV inhibitors have been suggested to be a new class of molecule for treating hyperglycemic conditions in diabetic patients. The recent approval of Merck's Sitagliptin (a DPP-IV-specific inhibitor) indicates that DPP-IV inhibition is a good target for new therapeutic agent development. The present study was conducted to evaluate the efficacies of a series of dipeptidyl derivatives with a sulfonamide moiety as DPP-IV inhibitors. Among these compounds, D-420720 was a potent inhibitor (Ki=39 nM), with a selectivity of 9160-fold over the DPP-II isozyme and elicits a hypoglycemic effect on oral glucose tolerance test with normal male ICR mice. Drug Dev Res 69: 514–525, 2008.
    Relation: DRUG DEVELOPMENT RESEARCH; 69(8):pages 514–519.
    Appears in Collections:[食品營養與保健生技學系] 期刊論文

    Files in This Item:

    There are no files associated with this item.

    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback